Nurse-led telephone of nausea and vomiting in cancer patients undergoing antineoplastic chemotherapy with Cisplatin
International Journal of Development Research
Nurse-led telephone of nausea and vomiting in cancer patients undergoing antineoplastic chemotherapy with Cisplatin
Received 04th July, 2018; Received in revised form 16th August, 2018; Accepted 21st September, 2018; Published online 30th October, 2018
Copyright © 2018, Paula Rachel Neves Espindola et al.,. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cisplatin is an antineoplastic used in treatment of some types of cancer. However, approximately 70 to 80% of patients undergoing this treatment are at risk of nausea and vomiting. Objective: Monitoring the occurrence of nausea and vomiting in cancer patients submitted to antineoplastic chemotherapy with cisplatin from the first treatment session. Methods: It is a quantitative, prospective and cross-sectional study carried out in a university hospital, with telephone follow-up with 50 patients who underwent chemotherapy with cisplatin from the first day of the cycle with cisplatin up to 72 hours after starting treatment. Results: The onset of symptoms was more frequent in the first 24 hours (64%) and 60% of the patients reported that they were unable to perform usual activities. Conclusion: The monitoring performed by the nurses through the telephone showed the importance and the need to accompany the patients in treatment with antineoplastic of high emetogenicity as it can provide support against the symptoms of nausea and vomiting to prevent related diseases.
